FDA OKs first and only drug for Hypereosinophilic Syndrome

GlaxoSmithKline (NYSE:GSK) announces FDA nod for Nucala for the treatment of adult and pediatric patients and older with Hypereosinophilic Syndrome.

The approval makes Nucala the first and only targeted biologic treatment to be approved for patients with this eosinophil-driven disease in the US.

Press Release

https://seekingalpha.com/news/3617443-fda-nods-first-and-only-drug-for-hes